Recently a large-scale, third-party research study published in the journal Scientific Research in Nature demonstrated Biospectal's ability to measure blood pressure as accurately as a standard blood pressure cuff. Biospectal launched two additional validation studies funded by the Bill & Melinda Gates Foundation and Global Grand Challenges Canada's Saving Lives at Birth initiative.
Biospectal OptiBP enables anyone in the world with a smartphone to turn their device into a connected, clinical-grade blood pressure monitor in the time it takes to download and install an app. The recent publication of a large-scale, third-party research study in Scientific Reports in Nature demonstrated Biospectal's ability to measure blood pressure as accurately as a sphygmomanometer, commonly referred to as a standard blood pressure cuff.
Biospectal now has launched two additional independent research and validation studies using Biospectal OptiBP. Currently underway in four low-resource countries, the studies center on the routine measurement and monitoring of blood pressure, assessment of hypertension during pregnancy, and enable global field testing and validation of Biospectal's OptiBP smartphone app and data platform integration with the WHO's Digital Antenatal Care module.
Funded by the Bill & Melinda Gates Foundation, the first independent study is underway in three countries — South Africa, Tanzania and Bangladesh — and is concentrated on routine blood pressure measurement and monitoring as well as hypertension disorders during pregnancy. The second independent study in Indonesia is being conducted with the Summit Institute for Development (SID) in collaboration with Ona Kenya Limited and is funded through Grand Challenges Canada's Saving Lives at Birth initiative, with additional backing from USAID, the Bill & Melinda Gates Foundation, Norwegian Agency for Development Cooperation (NORAD), the Korean International Cooperation Agency (KOICA) and the HRP Special Programme of Research, Development and Research Training in Human Reproduction. The study centers on hypertension disorders during pregnancy, including chronic hypertension, preeclampsia-eclampsia, preeclampsia superimposed on chronic hypertension and gestational hypertension. Findings from the two studies will be available in the first half of 2022.
The OptiBP medical-grade smartphone app uses a smartphone camera's lens to easily measure and record a user's blood pressure flow via their fingertip. Using proprietary algorithms and optical signal capture methods, Biospectal OptiBP then transforms the captured data into blood pressure values in approximately 20 seconds — half the time of a typical blood pressure cuff. The captured blood pressure data connects seamlessly with a user's clinicians to support treatment regimens that help improve health, longevity and quality of life.
Biospectal OptiBP for Android launched in public beta in January 2021. Biospectal OptiBP for iOS is planned for public beta launch in the second half of 2021.
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines